Search and analyze individual stocks with comprehensive metrics
Anuh Pharma Limited
Fundamental Score
Anuh Pharma Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ANUHPHR across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Excellent ROCE Performance (17.24%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Attractive Valuation (P/E: 18.60 vs Industry: 33.97)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Strong Revenue Growth (35.22%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (16.60% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (25.58% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (25.58% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (88.79x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹79.91 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (69.92%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
2 factors identified
Profit Decline Concern (-12.72%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Limited Institutional Interest (FII+DII: 0.03%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Anuh Pharma Limited
About ANUHPHR
Company Details
Market Information
Performance
ANUHPHR Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of ANUHPHR?
ANUHPHR is currently trading at ₹80.16 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of ANUHPHR shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of ANUHPHR and what does it mean?
ANUHPHR has a P/E ratio of 18.60x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹19 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.
How is ANUHPHR performing according to Bull Run's analysis?
ANUHPHR has a Bull Run fundamental score of 64.6/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 13.41%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does ANUHPHR belong to?
ANUHPHR operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Anuh Pharma Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for ANUHPHR?
ANUHPHR has an ROE of 13.41%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Anuh Pharma Limited generates profits from shareholders' equity. An ROE of 13% means the company generates ₹13 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is ANUHPHR's debt-to-equity ratio and what does it indicate?
ANUHPHR has a debt-to-equity ratio of 0.03, which indicates conservative financing with low financial risk. This means the company has ₹3 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is ANUHPHR's dividend yield and is it a good dividend stock?
ANUHPHR offers a dividend yield of 1.76%, which means you receive ₹1.76 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has ANUHPHR grown over the past 5 years?
ANUHPHR has achieved 5-year growth rates of: Sales Growth 16.60%, Profit Growth 25.58%, and EPS Growth 25.58%. This consistent double-digit growth indicates a strong business model and competitive positioning. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in ANUHPHR and why does it matter?
Promoters hold 69.92% of ANUHPHR shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does ANUHPHR compare with its industry peers?
ANUHPHR trades at P/E 18.60x vs industry average 33.97x, with ROE of 13.41% and ROCE of 17.24%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether ANUHPHR is outperforming its competitive set in profitability, growth, and valuation metrics.
What is ANUHPHR's market capitalization and what category does it fall into?
ANUHPHR has a market capitalization of ₹858 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for ANUHPHR?
Key ratios for ANUHPHR: ROE 13.41% (Good), ROCE 17.24%, P/E 18.60x, Debt-to-Equity 0.03, Interest Coverage 88.79x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is ANUHPHR stock and what is its beta?
ANUHPHR has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for ANUHPHR?
ANUHPHR has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹80.16, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in ANUHPHR?
Key risks for ANUHPHR include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.03), and operational challenges. The stock has a Fundamental Score of 64.6/100, indicating moderate risk requiring careful monitoring. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is ANUHPHR's operating profit margin and how has it trended?
ANUHPHR has a 5-year average Operating Profit Margin (OPM) of 10.23%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.
How is ANUHPHR's quarterly performance in terms of sales and profit growth?
ANUHPHR's recent quarterly performance shows YoY Sales Growth of 35.22% and YoY Profit Growth of -12.72%. This shows decent growth momentum in the business. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in ANUHPHR?
ANUHPHR has FII holding of 0.03% and DII holding of 0.00%, totaling 0.03% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.